LATEST VERSION
DEVELOPING · 19 NOV → 22 NOV 2026 · 4 EDITIONS · 20 OUTLETS
Daraxonrasib combination shows early promise in metastatic pancreatic cancer trial
How this story moved: how many newsrooms carried it at each run, when each one picked it up, how our summary's headline changed, and which figures and names held from the first reports to the latest. Everything here is counted from the coverage; none of it is a judgement of anyone's motives.
OUTLETS CARRYING THE STORY, RUN BY RUN
HOW OUR HEADLINE CHANGED · 2 HEADLINES
-
21 Nov, 00:25 UTC
Daraxonrasib-chemotherapy combination shows promise in early pancreatic cancer trial
-
21 Nov, 18:24 UTC
Daraxonrasib combination shows early promise in metastatic pancreatic cancer trial
WHAT HELD, WHAT CAME LATER
From the first reports to the latest
- Nothing ran from the first third of the coverage to the last.
Entered the story later
- 76.6% patients alive · from 20 Nov 09:36, 2 outlets
- 18 months your · from 20 Nov 09:36, 2 outlets
- Wungki Park · from 20 Nov 09:36, 2 outlets
- Michelle Mitchell · from 20 Nov 09:36, 2 outlets
Figures reported with different numbers
- cent patients: 60.7 (1 from 21 Nov 08:33) → 90 (1 from 21 Nov 08:33) → 90.2 (1 from 21 Nov 08:33) → 8 (1 from 21 Nov 12:25)
Matched by pattern, not read: a different number can be a correction, a rising count, or two different counts.